WHO approves first malaria drug for infants up to 5 kg to close treatment gap
WHO approves first malaria drug for infants up to 5 kg, closing treatment gaps for 30 million newborns in Africa; now calls for insecticide-treated nets.
WHO approval announced on World Malaria Day
The World Health Organization has approved the first anti-malarial formulation specifically designed for newborns and infants weighing up to 5 kilograms. The approval, announced on World Malaria Day (April 25), applies to a paediatric formulation of artemether‑lumefantrine intended for the youngest patients.
The decision aims to expand safe treatment options in malaria-endemic regions and to provide a standardised dose for infants who until now have often been given medicines formulated for older children. WHO framed the approval as a step to reduce the risks of incorrect dosing and adverse reactions in newborns treated for malaria.
Targeting a long-standing treatment gap
Health authorities estimate that roughly 30 million infants are born each year in malaria‑affected areas across Africa, many of whom face early exposure to the disease. Until this new formulation, clinicians frequently adapted doses meant for older children or relied on improvised methods, potentially increasing safety risks.
By approving a version of artemether‑lumefantrine tailored to infants up to 5 kg, WHO intends to provide clearer dosing guidance and reduce the uncertainty clinicians confront when treating very young patients. The move is expected to help harmonise national treatment protocols and make stock procurement more straightforward for ministries of health and humanitarian agencies.
Implications for child mortality and clinical practice
Children under five remain the group most vulnerable to malaria-related deaths, and WHO data indicate they account for a substantial share of malaria mortality in endemic countries. The new infant formulation could play a role in lowering fatality rates by improving early and appropriate treatment.
Clinicians and paediatric experts say having a product designed for newborns could reduce medication errors and adverse effects tied to off-label dosing. Public health programmes will need to adapt training materials, dosing charts, and supply chains to ensure the drug reaches frontline facilities and community health workers who care for infants.
Prevention remains central: treated nets and early protection
Alongside approval of the malaria drug for infants, WHO reiterated its longstanding prevention guidance, recommending widespread use of insecticide‑treated nets for both infants and adults. Preventive measures remain essential to limit mosquito bites and reduce the incidence of malaria among the most vulnerable groups.
WHO emphasised that treatment advances must be paired with vector control, early diagnosis, and access to care to achieve measurable reductions in illness and death. Insecticide‑treated nets, intermittent preventive therapy where applicable, and prompt testing and treatment form the complementary strategies WHO continues to promote.
Operational challenges and rollout considerations
Experts caution that regulatory approval is an important milestone but not the end of the process needed to deliver benefits on the ground. National regulatory authorities will need to incorporate the formulation into national guidelines, and procurement systems must be prepared to source and distribute the paediatric product.
Supply chain managers and public health officials will face logistical tasks such as forecasting demand, ensuring appropriate storage, and training health workers on dosing and administration for infants weighing under 5 kg. Funding partners and global procurement mechanisms may be called upon to subsidise early rollout in countries with the highest malaria burdens.
Monitoring safety and effectiveness in the field
WHO approval typically accompanies recommendations for post‑market monitoring to track safety, effectiveness, and programme implementation. Collecting real-world data from health facilities and national programmes will be important to identify any operational issues and to confirm the expected public health impact among newborns and infants.
Robust pharmacovigilance and reporting mechanisms will help detect rare adverse events and inform any necessary adjustments to clinical guidance. Close collaboration between ministries of health, clinicians, and international partners will be critical in the early months of introduction.
The approval of a paediatric artemether‑lumefantrine formulation marks a key development in malaria care for the youngest patients, but translating this into reduced deaths and improved health will depend on rapid, well-coordinated rollout, continued prevention efforts, and careful monitoring of outcomes.